EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 06 2025
0mins
Should l Buy EYPT?
Source: Newsfilter
Company Announcement: EyePoint Pharmaceuticals will have its CEO, Jay S. Duker, participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025, with a live webcast available for 90 days post-event.
Product Development: The company is advancing its lead product candidate, DURAVYU™, an investigational treatment for retinal diseases, currently undergoing Phase 3 trials for wet age-related macular degeneration and has shown positive results in diabetic macular edema.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EYPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EYPT
Wall Street analysts forecast EYPT stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.010
Low
20.00
Averages
31.50
High
43.00
Current: 13.010
Low
20.00
Averages
31.50
High
43.00
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
EYPT Options Trading Analysis and Strategies
- Put Option Appeal: The current bid for the $12.50 put option is $2.50, and if an investor sells this option, they commit to buying the stock at $12.50, effectively lowering their cost basis to $10.00, which is about a 4% discount from the current price of $13.03, making it attractive for those interested in EYPT shares.
- Return Potential Analysis: Should the put option expire worthless, the investor would realize a 20% return on their cash commitment, equating to an annualized yield of 36.69%, highlighting the potential attractiveness of this strategy in the current market environment.
- Call Option Returns: The $15.00 call option has a bid of $3.00, and if an investor buys EYPT shares at $13.03 and sells this call option, they could achieve a total return of 38.14% if the stock is called away at expiration, showcasing the high return potential of this strategy.
- Volatility Comparison: The implied volatility for the put option is 149%, while for the call option it is 147%, compared to a trailing twelve-month actual volatility of 73%, indicating a high market expectation for future volatility in EYPT shares, which necessitates careful risk assessment by investors.
See More
Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%
- Sector Recovery: The iShares Biotechnology ETF surged 29.51% year-to-date by December 2025, while the State Street SPDR S&P Biotech ETF achieved an even higher gain of 35.84%, indicating a significant recovery in investor confidence in the biotech sector.
- Surge in M&A Activity: Six of the year's ten largest biopharma deals occurred in Q4, with Johnson & Johnson spending $14.6 billion on Intra Cellular Therapies, signaling a strong commitment from big pharma to expand their pipelines through acquisitions.
- FDA Approvals Boost Innovation: The FDA approved 44 new therapies in 2025, with 26 approvals in the second half, including Cytokinetics' Myqorzo after 27 years, highlighting a supportive regulatory environment for innovation.
- Clinical Trial Successes: Structure Therapeutics saw its stock more than double after its obesity drug trials showed over 15% weight loss in patients, demonstrating the direct impact of clinical success on company valuations.
See More
EyePoint CEO Jay Duker to Present at 2026 J.P. Morgan Healthcare Conference
- Key Conference Presentation: EyePoint, Inc. CEO Jay S. Duker will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, showcasing the company's innovative advancements in retinal disease treatments, which is expected to attract investor interest and enhance corporate visibility.
- Clinical Trial Progress: EyePoint's lead product DURAVYU™ is currently undergoing Phase 3 pivotal trials, with topline data expected in mid-2026, which will provide crucial support for the company's future market launch and fundraising efforts.
- Product Innovation: DURAVYU™ combines the selective tyrosine kinase inhibitor vorolanib with next-generation bioerodible Durasert E™ technology, aimed at improving the quality of life for patients with serious retinal diseases, demonstrating the company's technological edge in the biopharmaceutical sector.
- Market Potential: EyePoint is committed to partnering with the retina community to drive long-term value creation, having approved four drugs over three decades and treated tens of thousands of eyes, indicating a strong foundation and future growth potential in the retinal disease treatment market.
See More
EyePoint Grants 137,000 Stock Options to New Employees as Inducement Awards
- Stock Option Grant: EyePoint granted a total of 137,000 non-statutory stock options to nine new employees on December 15, 2025, with an exercise price of $16.40 per share, aimed at attracting and retaining talent to enhance the company's human resource advantage in the competitive biopharmaceutical industry.
- Incentive Mechanism: The option grants comply with NASDAQ Listing Rule 5635(c)(4) and were approved by the Compensation Committee, reflecting the company's strategic decision to attract new employees and enhance loyalty and engagement through long-term incentive mechanisms.
- Option Structure: The granted options vest over four years, with 25% vesting in the first year and the remainder vesting monthly, which not only aids in long-term employee retention but also ensures their ongoing contributions to the company's growth.
- Market Outlook: EyePoint is committed to developing innovative therapeutics for serious retinal diseases, and as the clinical trials for DURAVYU™ progress, the stock option grants will further motivate employees to strive for the company's long-term success, enhancing its competitive position in the biopharmaceutical sector.
See More
EyePoint Grants 137,000 Stock Options to New Employees as Inducement Awards
- Stock Option Grant: On December 15, 2025, EyePoint granted a total of 137,000 non-statutory stock options to nine new employees, with an exercise price of $16.40 per share, aimed at attracting and retaining talent to enhance team stability.
- Incentive Structure: The options, compliant with NASDAQ Listing Rule 5635(c)(4), will vest over four years with 25% vesting on the first anniversary and the remainder in monthly installments, ensuring continued employee contribution during their tenure.
- Strategic Implications: By implementing such incentive measures, EyePoint not only attracts industry talent but also enhances employee loyalty and engagement, thereby boosting the company's innovation and competitive edge in retinal disease treatments.
- Future Outlook: EyePoint is committed to developing innovative therapies like DURAVYU™, with pivotal clinical trial data expected in mid-2026, and the stock option grants will help maintain team stability and execution capability during this critical period.
See More
Market Update: Health Care Stocks Show Varied Performance Ahead of Wednesday's Opening Bell
- Market Overview: Health care stocks showed mixed performance before the market opened on Wednesday.
- Key Fund Mentioned: The Health Care Select Sector SPDR Fund (XLV) was specifically noted in the context of the market activity.
See More
EYPT Options Trading Analysis and Strategies
- Put Option Appeal: The current bid for the $12.50 put option is $2.50, and if an investor sells this option, they commit to buying the stock at $12.50, effectively lowering their cost basis to $10.00, which is about a 4% discount from the current price of $13.03, making it attractive for those interested in EYPT shares.
- Return Potential Analysis: Should the put option expire worthless, the investor would realize a 20% return on their cash commitment, equating to an annualized yield of 36.69%, highlighting the potential attractiveness of this strategy in the current market environment.
- Call Option Returns: The $15.00 call option has a bid of $3.00, and if an investor buys EYPT shares at $13.03 and sells this call option, they could achieve a total return of 38.14% if the stock is called away at expiration, showcasing the high return potential of this strategy.
- Volatility Comparison: The implied volatility for the put option is 149%, while for the call option it is 147%, compared to a trailing twelve-month actual volatility of 73%, indicating a high market expectation for future volatility in EYPT shares, which necessitates careful risk assessment by investors.
See More
Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%
- Sector Recovery: The iShares Biotechnology ETF surged 29.51% year-to-date by December 2025, while the State Street SPDR S&P Biotech ETF achieved an even higher gain of 35.84%, indicating a significant recovery in investor confidence in the biotech sector.
- Surge in M&A Activity: Six of the year's ten largest biopharma deals occurred in Q4, with Johnson & Johnson spending $14.6 billion on Intra Cellular Therapies, signaling a strong commitment from big pharma to expand their pipelines through acquisitions.
- FDA Approvals Boost Innovation: The FDA approved 44 new therapies in 2025, with 26 approvals in the second half, including Cytokinetics' Myqorzo after 27 years, highlighting a supportive regulatory environment for innovation.
- Clinical Trial Successes: Structure Therapeutics saw its stock more than double after its obesity drug trials showed over 15% weight loss in patients, demonstrating the direct impact of clinical success on company valuations.
See More
EyePoint CEO Jay Duker to Present at 2026 J.P. Morgan Healthcare Conference
- Key Conference Presentation: EyePoint, Inc. CEO Jay S. Duker will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, showcasing the company's innovative advancements in retinal disease treatments, which is expected to attract investor interest and enhance corporate visibility.
- Clinical Trial Progress: EyePoint's lead product DURAVYU™ is currently undergoing Phase 3 pivotal trials, with topline data expected in mid-2026, which will provide crucial support for the company's future market launch and fundraising efforts.
- Product Innovation: DURAVYU™ combines the selective tyrosine kinase inhibitor vorolanib with next-generation bioerodible Durasert E™ technology, aimed at improving the quality of life for patients with serious retinal diseases, demonstrating the company's technological edge in the biopharmaceutical sector.
- Market Potential: EyePoint is committed to partnering with the retina community to drive long-term value creation, having approved four drugs over three decades and treated tens of thousands of eyes, indicating a strong foundation and future growth potential in the retinal disease treatment market.
See More
EyePoint Grants 137,000 Stock Options to New Employees as Inducement Awards
- Stock Option Grant: EyePoint granted a total of 137,000 non-statutory stock options to nine new employees on December 15, 2025, with an exercise price of $16.40 per share, aimed at attracting and retaining talent to enhance the company's human resource advantage in the competitive biopharmaceutical industry.
- Incentive Mechanism: The option grants comply with NASDAQ Listing Rule 5635(c)(4) and were approved by the Compensation Committee, reflecting the company's strategic decision to attract new employees and enhance loyalty and engagement through long-term incentive mechanisms.
- Option Structure: The granted options vest over four years, with 25% vesting in the first year and the remainder vesting monthly, which not only aids in long-term employee retention but also ensures their ongoing contributions to the company's growth.
- Market Outlook: EyePoint is committed to developing innovative therapeutics for serious retinal diseases, and as the clinical trials for DURAVYU™ progress, the stock option grants will further motivate employees to strive for the company's long-term success, enhancing its competitive position in the biopharmaceutical sector.
See More
EyePoint Grants 137,000 Stock Options to New Employees as Inducement Awards
- Stock Option Grant: On December 15, 2025, EyePoint granted a total of 137,000 non-statutory stock options to nine new employees, with an exercise price of $16.40 per share, aimed at attracting and retaining talent to enhance team stability.
- Incentive Structure: The options, compliant with NASDAQ Listing Rule 5635(c)(4), will vest over four years with 25% vesting on the first anniversary and the remainder in monthly installments, ensuring continued employee contribution during their tenure.
- Strategic Implications: By implementing such incentive measures, EyePoint not only attracts industry talent but also enhances employee loyalty and engagement, thereby boosting the company's innovation and competitive edge in retinal disease treatments.
- Future Outlook: EyePoint is committed to developing innovative therapies like DURAVYU™, with pivotal clinical trial data expected in mid-2026, and the stock option grants will help maintain team stability and execution capability during this critical period.
See More
Market Update: Health Care Stocks Show Varied Performance Ahead of Wednesday's Opening Bell
- Market Overview: Health care stocks showed mixed performance before the market opened on Wednesday.
- Key Fund Mentioned: The Health Care Select Sector SPDR Fund (XLV) was specifically noted in the context of the market activity.
See More
